John Sampson to lead Duke’s physician practice of over 1,500 members

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John Sampson was elected president of the Private Diagnostic Clinic, the physician practice of Duke Health, with 1,650 members practicing in Duke hospitals and more than 100 clinics in North Carolina.

Sampson will continue to serve as chair of the Duke Department of Neurosurgery. The PDC is one of the first and the largest academic multi-specialty group practices in the U.S., with 1.7 million patient visits in FY18 and $850 million in total revenue.

In addition to patient care, PDC members conduct research and serve as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke’s clinical, research, and academic missions.

In this role, Sampson will provide strategic direction and oversight of the financial and management aspects of the physician organization. This includes implementing initiatives to best position the PDC for continued growth and success, and leading, on behalf of PDC members, the due diligence and negotiations of the potential integration of the PDC and Duke University Health System.

Sampson is the Robert H. and Gloria Wilkins Distinguished Professor and co-leader of the Duke Cancer Institute Neuro-Oncology program. He is a recognized leader in the surgical resection and experimental treatment of complex brain tumors.

He currently focuses his clinical practice on treating patients with benign and malignant brain tumors and divides his time between his clinical practice and an active research laboratory investigating new modalities of direct brain tumor infusion and immunotherapy.

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login